07:48 AM EDT, 09/06/2024 (MT Newswires) -- GSK (GSK) said Friday that a phase 3 trial evaluating Nucala in adults with chronic obstructive pulmonary disease met its primary endpoint.

The British pharmaceutical company said the study results showed a statistically significant and clinically meaningful reduction in the annualized rate of moderate to severe exacerbations compared to placebo.

Shares of GSK were up 1% in recent premarket activity.

Price: 43.58, Change: +0.45, Percent Change: +1.04